SYDNEY, Australia – July 24, 2026
Immutep Limited has announced that an abstract from its investigator-initiated Phase II EFTISARC-NEO trial has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled to take place October 23–27, 2026, in Madrid, Spain. The accepted abstract highlights health-related quality of life (HRQoL) data from patients receiving eftilagimod alfa (efti), pembrolizumab, and radiotherapy as neoadjuvant treatment for soft tissue sarcoma (STS). The presentation underscores the continued clinical development of efti, Immutep’s first-in-class MHC Class II agonist, and reflects growing interest in its potential to improve treatment outcomes while maintaining patient quality of life. The full abstract will be published on the ESMO Congress 2026 website on October 19, 2026, with the presentation also becoming available through the company’s website.
Phase II Trial Highlights Quality of Life in Soft Tissue Sarcoma
The EFTISARC-NEO Phase II trial (NCT06128863) is evaluating the combination of eftilagimod alfa, pembrolizumab, and radiotherapy in patients with soft tissue sarcoma, a rare group of cancers affecting connective tissues. The accepted ePoster presentation focuses on health-related quality of life (HRQoL) during neoadjuvant treatment, an increasingly important measure alongside clinical efficacy in cancer care. The abstract, authored by Dr. Pawel Teterycz of the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, has been assigned Presentation No. 3788eP. The inclusion of HRQoL findings at one of the world’s leading oncology conferences demonstrates the importance of understanding how innovative immunotherapy combinations affect patients throughout treatment.
Efti Advances Immutep’s Immunotherapy Pipeline
Eftilagimod alfa (efti) is Immutep’s first-in-class MHC Class II agonist, designed to activate the immune system and enhance anti-tumor responses. The therapy represents one of the company’s leading clinical assets as it advances a diversified pipeline targeting cancer and autoimmune diseases through Lymphocyte Activation Gene-3 (LAG-3) biology. Immutep has established itself as a pioneer in developing LAG-3-based immunotherapies, aiming to stimulate or regulate immune responses depending on disease indications. The company’s research strategy focuses on combining efti with established cancer therapies, including immune checkpoint inhibitors such as pembrolizumab, to potentially improve treatment effectiveness across multiple oncology settings.
Advertisement
ESMO Presentation Strengthens Clinical Development Strategy
Presentation at the ESMO Congress 2026 provides Immutep with an important opportunity to showcase additional clinical evidence supporting eftilagimod alfa in oncology. The congress is recognized globally as a premier scientific meeting where researchers present significant advances in cancer treatment and clinical research. By sharing HRQoL data alongside ongoing clinical development efforts, the company continues to build evidence supporting the broader therapeutic potential of efti in combination treatment strategies. As Immutep progresses its late-stage immunotherapy pipeline, presentations at major international conferences remain a key component of its strategy to engage the global oncology community, strengthen scientific collaborations, and support the future development of innovative therapies for patients with difficult-to-treat cancers.
Source: Immutep press release
